Abstract:2576 Background: Tumor microenvironment (TME) heterogeneity leads to the discrepancy of survival prognosis and clinical treatment response for HCC patients. Although the documented molecular subtypes moderately describe the TME heterogeneity and characteristics, their clinical application is constrained by several issues. Methods: We integrated three single-cell datasets from 39 HCC patients to describe the TME landscape and identified prognosis-related cell subclusters. Unsupervised clustering of subcluster-specific markers (SSMs) was performed to generate transcriptomic subtypes. The predictive value of these molecular subtypes for prognosis and treatment response was explored in multiple external HCC cohorts and Xiangya real-world HCC cohort with patients who received immune checkpoint blockade (ICB) therapy. Cancer stemness was estimated using bioinformatic methods and in vivo and in vitro experiments. The features of TME were further validated using single-cell RNA-seq and immune repertoire sequencing, mass cytometry (CyTOF) and multiplex immunofluorescence (mIF). Ultimately, we constructed prognosis-related score (PRS)based on machine learning algorithm, and identified the potential therapeutic targets and agents for high-PRS patients. Results: The comprehensive single-cell analysis provided a high-resolution depiction of TME heterogeneity in HCC and confirmed 6 cell subclusters of prognostic relevance. Five transcriptomic subtypes were constructed using SSMs, which possessed different clinical prognosis, stemness characteristics, immune landscape and therapeutic responses. Class 1 indicated an inflamed phenotype with better clinical outcomes, while Class 2 and class 4 demonstrated immune-deserted phenotypes lacking T cells infiltration. Class 5 and class 3 indicated inhibitory tumor immune microenvironment enriched regulatory T cells and suppressive immune checkpoints. Multiple therapeutic cohorts suggested that Class 5 and class 3 were sensitive to ICB and targeted therapy, while Class 1 and Class 2 were more responsive to transcatheter arterial chemoembolization treatment (TACE). Class 4 displayed resistant to all conventional HCC therapies. The PRS performed well in prognostic prediction in multiple HCC cohorts. Four potential therapeutic agents and four targets were further identified for high-PRS HCC patients. Conclusions: Our study generated a clinically valid molecular classification, thereby providing guidance for precision medicine in HCC patients.

Differentiation therapy: Unlocking phenotypic plasticity of hepatocellular carcinoma

Heterogeneous Responses in Hepatocellular Carcinoma: the Achilles Heel of Immune Checkpoint Inhibitors.

Small Molecule‐Induced Differentiation As a Potential Therapy for Liver Cancer

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

<p>Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives</p>

In VitroandIn VivoHepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases

Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF‐kB signaling pathways synergistically

Differentiation of Bone Marrow Derived Thy-1 + Β 2 M − Cells into Hepatocytes Induced by Coculture with Transgenic CFSCs

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma

A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets

CXCR7 Correlates with the Differentiation of Hepatocellular Carcinoma and Suppresses HNF4α Expression Through the ERK Pathway.

New advances in the treatment of intermediate and advanced hepatocellular carcinoma

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma

Differentiation of Hematopoietic Stem Cells into Hepatocytes in Liver Fibrosis in Rats

Single-cell RNA sequencing revealed potential targets for immunotherapy studies in hepatocellular carcinoma

Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells

Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors

Cell Differentiation Trajectory in Liver Cirrhosis Predicts Hepatocellular Carcinoma Prognosis and Reveals Potential Biomarkers for Progression of Liver Cirrhosis to Hepatocellular Carcinoma

Potential targets and therapeutics for cancer stem cell-based therapy against drug resistance in hepatocellular carcinoma